Palvella Therapeutics (PVLA) Capital Expenditures (QoQ) (2014 - 2023)
Powered by 
Analysis
Palvella Therapeutics (PVLA) Capital Expenditures (QoQ) (2014 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -118.84% |
| Sep 30, 2023 | 2.99% |
| Jun 30, 2023 | 39.58% |
| Mar 31, 2023 | 536.36% |
| Dec 31, 2022 | -132.35% |
| Sep 30, 2022 | -94.59% |
| Jun 30, 2022 | 61.70% |
| Mar 31, 2022 | 13.74% |
| Dec 31, 2021 | -2.29% |
| Sep 30, 2021 | 52.84% |
| Jun 30, 2021 | 717.86% |
| Mar 31, 2021 | -95.16% |
| Dec 31, 2020 | 168.81% |
| Sep 30, 2020 | -179.17% |
| Jun 30, 2020 | -44.94% |
| Mar 31, 2020 | 63.86% |
| Dec 31, 2019 | 406.90% |
| Sep 30, 2019 | -75.13% |
| Jun 30, 2019 | 671.07% |
| Mar 31, 2019 | -78.58% |